Capitalizing on over 20 years of structural genomics and structural biology expertise using high-throughput protein X-ray crystallography, Accelero Biostructures uses its ABSTM and ABS-OneStepTM platforms for structure-based drug discovery and protein engineering. ABSTM provides a unified pipeline for protein X-ray crystallography and structural biology to pharmaceutical and biotechnology companies to support structure-based drug discovery. ABS-OneStepTM is our next-generation platform, being developed with non-dilutive SBIR funding, focused on using fragment-based drug discovery for the discovery and development of novel therapeutics.
The science behind AcureX is based on the game-changing discovery at Stanford of a new target that is relevant to stopping a range of neurodegenerative diseases, starting with Parkinson’s disease (PD), currently impossible with any drug on the market. We have shown that reducing this new target is indeed neuroprotective in multiple model systems. We have already identified promising small molecules by high-throughput and in silico screens. We plan to optimize the lead compounds that fit the human blood-brain barrier penetrant profile, select the development candidate and move forward to clinical trials.
Aichemist Metal Inc. focuses on the development of ultra-thin nanofiber reinforced materials for next-generation lithium batteries that offer a wide range of benefits in the EV, robotics, data center, and display markets. These nanofiber-reinforced materials, which are a composite of biopolymer nanofibers and copper, are created via an electrochemical process and incorporated with ultra-thin lithium metals, silicon electrodes and solid-state polymer batteries.
Ambagon Therapeutics is discovering and developing first-in-class drugs through targeted stabilization of protein complexes. Ambagon drugs stabilize the naturally occurring interaction between the 14-3-3 class of adaptor proteins and their oncogenic client proteins, modulating the activity of the client protein. Because many 14-3-3 client proteins are difficult to drug target classes, Ambagon’s approach opens up novel target space as well as having an innovative mechanism of action.
Applaud Medical, Inc. was established to develop and commercialize an innovative new treatment for kidney stones, a condition diagnosed in more than 2 million individuals every year in the U.S. alone. Treating large stones currently requires anesthesia in an operating room. The current least invasive surgical intervention only renders 50% of patients stone-free. Applaud's innovative kidney stone treatment will for the first time allow urologists to effectively treat 5-15 millimeter stones with a simple outpatient procedure.
The major goal of Apricity Therapeutics Inc. (Apricity) is to exploit influx transporters to enhance the efficacy and reduce the toxicity of drugs. Cancer chemotherapy is the pharmacologic class of drugs that derives the greatest benefit from exploitation of influx transporters. Our primary focus is to target marketed anti-cancer drugs with narrow therapeutic indices to highly expressed influx transporters on cancer cell membranes.
Aptah is a biotech company that aims to support medical advancements by introducing innovative technologies into the drug discovery process. At Aptah’s, they modulate the spliceosome machinery and thus, the pre-mRNA, which ensures the precise control of the transcription step and modulation of specific gene expression - not only silencing, but also editing the pre-mRNA by hacking the spliceosome machinery.
Atropos creates senescence-modulating therapeutics ("senomodulators") that may be used to treat aging-related diseases and cancers. We begin with our proprietary FATES discovery platform to identify compounds that critically regulate the rate at which senescent cells form. Our pipeline includes potential solutions for inherited genetic aging, acquired senescence, and other aging syndromes that involve heightened senescence and cancers that may be resistant to cytostatic drugs because they suppress the senescence pathway. Atropos is currently doing preclinical studies toward lead identification.
We are a precision oncology company developing novel small molecules that target aggressive forms of cancer. Patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. Our current program is targeting specific gene alterations that occur in the DNA of patients, which transform into key drivers of tumor growth. At Biomea, we leverage our internal drug design expertise and compliment it with computational technology to build novel medicines for the future. We have significantly invested in the upfront development of our targeted therapies and are conducting broad preclinical development programs.
CAGE Biosciences Inc. is focused on developing novel and valuable products for dermatology. Our mission is to minimize the pervasive use of systemic drugs for the treatment of dermal diseases and symptoms. CAGE’s lead product is based on Ionic Liquid technology in-licensed from Prof. Samir Mitragotri's laboratory at the University of California, Santa Barbara. Ionic Liquids offer broad spectrum antimicrobial and anti-inflammatory properties along with enhancement of solubility and permeability. These properties combined with excellent biocompatibility make them attractive as and for formulating effective products for dermatology.
Celldom, Inc., founded in 2016 in Durham, North Carolina, is developing next generation, single-cell analysis technology to advance research, drug discovery and development by illuminating diversity in cell populations.
Clover Therapeutics discovers and develops precision medicines for diseases of aging with a genetics-driven approach. We have a genetically diverse, longitudinal, and re-contactable Medicare patient network with comprehensive clinical data as the foundation of our clinico-genomic studies. We are currently advancing preclinical drug programs in Age-related Macular Degeneration (AMD), and conducting two observational clinical studies in this disease.
Coral Genomics develops therapeutics that effectively treat disease across the diversity of genetic backgrounds. Powered by our custom bank of cell lines, we work with biotech partners in the preclinical stage to identify variation in therapeutic response. We recommend strategies for overcoming that variation and inform patient selection during the clinical trial process.
At CRISP-HR Therapeutics, our mission is to develop novel genetic engineering platforms and cellular therapeutics to improve human wellbeing. As a first step, we have developed a next-generation CRISPR based genetic engineering platform, Cas9-HR, which significantly reduces cellular toxicity and increases error-free editing efficiency. We plan to use our platform to develop cellular therapeutics for a variety of indications; and finally deliver on CRISPR/Cas9’s initial promise to radically improve patient outcomes, quality of life, and overall human wellbeing.
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson’s Disease, Alzheimer’s Disease and less common neurodegenerative disorders.
The company is developing small molecule drugs targeting a novel mechanism in the brain to modify disease pathology, and alleviate disabling symptoms, such as cognition, executive function, and motor and autonomic dysfunction, all of which can severely impact quality of life. CuraSen’s drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration.
Cypre is developing technologies that drastically improve drug development and precision medicine for cancer patients. We are pioneering new ways to recreate and study the tumor microenvironment, opening the door for a new generation of therapeutics and patient success.
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies to promote healthy lifespan. Senescent cells accumulate and play a central role in the pathogenesis of a number of age related diseases. Deciduous was founded on the premise that accumulation of senescent cells is due to a failure of the immune system to eliminate them. In order to solve this problem, Deciduous is developing therapies to activate the endogenous immune cell population that normally carries out immune surveillance and clearance of senescent cells.
Delve Therapeutics is an early-stage company researching new oncolytic viruses to treat metastatic cancers. Their team is investigating possible ways to use synthetic biology to make viruses tumor-selective without reducing their cancer cell-killing potential.
Eidos Therapeutics is developing a novel treatment for transthyretin (TTR) amyloidosis (ATTR), a progressive, fatal disease affecting multiple organs including the heart and peripheral nerves. Current treatment options focus on managing the symptoms of the conditions, but do not address the underlying cause of the disease: TTR tetramers destabilized by mutations or age. Eidos’ lead compound, AG10, is a small molecule that binds and stabilizes TTR in the blood, preventing the formation of amyloid and potentially halting progression of the disease. Launched in 2016 after years of research supported by Stanford’s TRAM and SPARK programs, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to provide a safe, effective treatment for ATTR as quickly as possible.
Dorian Therapeutics is an anti-aging company focusing on blocking the process of cellular senescence at early stages.The company develops therapeutics to modulate stem cell pathways affected during aging.
Based upon ten years of dermatological research with renowned French and US institutions, ELSI attacks the damage caused by beauty products and the environment on our skin.
We are disrupting the $120B health and beauty industry with personalized & science-backed clean skincare for sensitive skin (special focus on the skin microbiome), supported by advanced analytics and a scientific diagnosis.
ELSI was awarded in 2019 the French-American Entrepreneurship Awards and Joined JLABS SF in 2020.
Engine Biosciences is a venture-backed technology company integrating experimental biology and data science to map and decipher complex biological networks for more effective and efficient drug discovery. Engine’s technologies culminate from several years of research by our scientific founders who include faculty members of MIT, Harvard, Mayo Clinic, and UCSD, and our leadership team is applying our previous successful company building experiences to Engine to advance treatments to patients faster.
Applications of our broad platform have included rational combination therapy development, drug repurposing, novel drug discovery, and precision medicine enablement, some results of which have been published in leading peer-reviewed journals. Engine is actively using its technology in a range of indications, through internal work and partnerships with Fortune 500 companies and leading research institutions, and is currently operating in the San Francisco Bay Area and in Singapore.
Envivo has developed CapScan®, a non-invasive device that collects microbiome samples from all regions of the human GI tract. The discoveries contained in these samples will lead to new cures for human diseases.
ExoPolymer is a biotechnology company focused on the production of unique, high performance biopolymers, or hydrocolloids, for the healthcare, personal care, food, pharmaceutical, and energy industries. Our technology involves the development of a robust, safe, and economical biological fermentation platform for the production of proprietary, next-generation molecules that are substantially improved over currently available products.
Fellow, the men’s health experts lifting the veil on fertility to equip every man with the guidance to reach his peak.
In response to the decline in men’s sperm count, there is a need for increased awareness and access to sexual health services for men. Fellow addresses this need by developing products that help men understand their fertility and take action to reach their personal goals.
Florica Therapeutics uses cutting edge technology to create therapeutics that address degenerative diseases of aging. The hypothalamus is a part of the brain that serves as a master regulator of aging. Essential physiological functions crucial to homeostasis are controlled by the hypothalamus region of the brain. Our goal is to pioneer therapeutics based on the hypothalamus stem cell to treat musculoskeletal and cognitive degeneration, thereby increasing both human health span and lifespan.
Foundery Innovations is an emerging company focused on knowledge-based prioritization and prosecution of target opportunities in the growing immunotherapy space. Integrating the immunology expertise and decades of therapeutic development background of the founders, we are expediting the timelines required for an academic concept to become a drug candidate. Foundery develops biologics with the potential to cure high unmet need diseases caused by an imbalance in immunity.
GALT was founded with the realization that while the Next Generation Sequencing (NGS) revolution has transformed discovery capabilities in microbiology and molecular biology, this revolution has caused downstream product development capabilities to be a costly and challenging bottleneck. Our aim is to obliterate this bottleneck.
We are committed to enabling and supporting our customers and partners in the discovery, development, and commercialization of next generation microbial products, and advancing the understanding of microbial systems overall, by providing high throughput instruments and tools for the microbial research and product development communities.
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options. We focus on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. There are 100 known glycosylation disorders. Glycomine is currently addressing 2 disorders of glycosylation: CDG-Ia and Ngly1 deficiency. Glycomine’s therapeutic approach relies on the design and construction of nano-vehicles for efficient delivery of replacement therapies into affected cells and tissues.
GPCR Therapeutics USA is a newly incorporated Biotechnology company in the Bay area originatinating from GPCR Therapeutics Inc., Korea. Our mission is to discover and develop innovative therapeutics targeting cancer based on the novel science of G protein coupled receptors (GPCR) heteromers. The most advanced clinical candidate, Burixafor, is planned to initiate a clinical trial in the US next year, focusing on our CXCR4 heteromer hypothesis. Additionally, we will be utilizing our technologies to identify key GPCR heteromers as therapeutics targets in Oncology. Dr. Pina Cardarelli will be heading up the team of talented researchers that will be expanding in the coming years.
GraphWear is replacing blood and urine diagnostic tests with a non-invasive sweat test. Sweat is diluted and ultra-filtered blood and has the same bio molecular information as blood, only in minuscule concentrations. GraphWear has developed a non-invasive flexible sensor that can tap into this information for real-time healthcare monitoring, using nanotechnology.
IHP Therapeutics is developing IHP-009, a Phase 3 ready new molecule to treat patients hospitalized with COVID-19. Our pipeline programs include novel carbohydrate-based drugs to treat inflammation and the pathologies of infectious diseases.
Exponentially better health requires examination and integration of omics, clinical, and behavioral data to create personalized plans of action for measurable outcomes. Using machine learning, we synthesize personal data with our expertise in systems biology to put control back in the hands of individuals who seek optimal performance and productivity.
Jupiter Therapeutics is a platform biotechnology company focused on creating a new class of cell-membrane based therapeutics. Jupiter uses cell engineering to make customized vesicles for immuno-oncology, gene therapy, and targeted drug delivery. Our first application in immuno-oncology is a highly feasible and differentiated approach that addresses major issues with CAR T-cells and bispecific antibodies.
Magnamosis, Inc. has the license to develop the Harrison Ring™, a cheap and effective alternative to surgical staplers. Under the guidance of its president, Michael Harrison, MD, Magnamosis Inc. is currently optimizing the device for colorectal and other GI tract uses.
MEDIC's product is a research tool/platform that contains millions of tumor variations we semi-artificially create with CRISPR and 3D cancer models. We use this platform to systematically discover biomarkers and synergistic drug combinations for pre-clinical/clinical oncology drugs from pharmaceutical companies and to identify novel drug targets for cancer.
NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yet gentle and non-perturbative manner. Cargo delivery via NanoStraws will drastically reduce the working steps, costs and technical difficulties involved in cell therapy manufacturing. By overcoming viability and manufacturing challenges plaguing traditional viral-based development, NAVAN is actively pursuing innovative therapies in a broad range of indications via strategic collaboration with numerous biopharma companies.
The NeuroSave mission is to prevent and treat ischemic brain injury by rapidly delivering the benefits of therapeutic hypothermia to the brain while protecting the body from the negative effects of cooling. NeuroSave offers the well-known neuroprotective benefits of this established therapy by using an improved delivery system that targets cooling to the brain without breaking the skin. Our system circulates cold fluid in the aerodigestive tract which cools the blood in the carotid and vertebral arteries, resulting in rapid brain-targeted cooling. This approach avoids the systemic complications commonly associated with a cold body core that can include abnormal heart rhythms, suppressed immune function, bleeding and transfusion.
OneSkin believes in the power of data and technology to fight our oldest enemy - aging. Aging is the major risk factor for many modern diseases and the skin is one of the most affected organs. We are harnessing the most advanced tools in tissue engineering and molecular biology to find molecules able to truly reverse skin aging. Our unique platform combines real human skin models and molecular markers to discover and produce the first generation of molecules for personalized anti-aging skincare products, scientifically proved for preventing or reverse aging.
Origen Hydrogen is commercializing a breakthrough AEM electrolyzer technology to produce green hydrogen. Green hydrogen can play a versatile role in reducing CO2 emissions for steel and fertilizer production, long-term energy storage, and as a fuel for semi-trucks, ships and airplanes. By eliminating the requirement for expensive metal components and catalysts due to a non-acidic environment, Origen enables a credible path to $1/kg green hydrogen. Our team has industry and R&D experience from BP, Stanford, Air Liquide NREL, Linde, GM, FuelCell Energy and MIT.
Pandorum Technologies Inc. is a biotechnology company with a focus on tissue engineering and regenerative medicine. At Pandorum, we build 3D functional tissues through a combination of cells, gels and cell modulators, using self-assembly, 3D printing and other fabrication methods to construct desired tissue like micro-architectures. Our proprietary technology platform is currently designed to develop functional human tissues, such as bio-engineered Cornea and Liver, intended for medical research and therapeutic applications.
Paramune focuses on novel molecular mechanisms to treat cancers and autoimmune diseases more effectively. Our targets arise from transformative new insights into disease pathology. We employ a variety of next-generation biologic formats including monoclonal antibodies, bispecifics, engagers and antibody cocktails to make possible the most favorable activity and safety profiles. Our approaches target disease mechanisms at the fundamental level, and as a result have the potential to achieve superior results as compared to current therapeutic approaches.
PHINOMICS uses circular DNA, an early marker of genetic change and physiological response, to diagnose disease and radically improve human health. By isolating and sequencing the circular genome (the “Circulome"), we solve a genetic puzzle that unlocks a universal “stage-zero” diagnostic for disease. At scale, circulome data will revolutionize diagnostics and identify new therapies.
Provenance Biofabrics is harnessing breakthroughs in tissue engineering and synthetic biology to make the next generation of leather. By synthesizing and programming collagen, the building block of skin, we are working to reinvent our oldest consumer material, sustainably and with no animals harmed.
PTM Therapeutics is focused on developing antibody therapeutics targeting post-translational modifications including glycans. Its primary asset, PTM-001 is being developed for the treatment of Inflammatory Bowel Disease (IBD). Unlike existing IBD therapies PTM-001 does not directly target the immune system but instead, promotes intestinal mucosal wound healing and has demonstrated promising efficacy in in vivo IBD models.
Ravel Biotechnology is commercializing an analytic technology platform capable of early disease detection from cell-free DNA. The company was founded in 2018 and is based in San Francisco, California. Early detection of disease through population level screening has led to decreased mortality and lowered healthcare costs for a set of diseases. Our technology enables the accelerated development and validation of screening tests for a wide range of diseases from a single analyte, cell-free DNA. Thus providing the opportunity to screen for a multitude of diseases from a single blood draw.
Regencor Inc. is focused on developing a new therapy to regenerate the human heart after a heart attack. The therapy is delivered by existing standard of care coronary revascularization procedures. The Company has discovered that a hypo-glycosylated variant of the normal circulating human protein, Follistatin-Like 1 (hgFSTL-1), regenerates lost cardiac muscle and blood vessels, and significantly reduces scar volume when delivered to the adult mammalian heart after infarction. This structural regeneration translates into sustained and clinically significant improvement in left ventricular performance measured by echocardiography and MRI imaging.
The goal of the therapy is to regenerate cardiac muscle, restore contractile function and prevent progression to heart failure after myocardial infarction.
Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage. We are targeting a class of pathological age associated compounds termed Advanced Glycation End Products (AGEs) which build up on long lived proteins like collagen. AGE accumulation is implicated in multiple diseases of aging, thus Revel Pharmaceuticals is strategically position to develop therapeutics across multiple indications.
RubrYc Therapeutics is a discovery-stage therapeutic antibody business focused on addressing unmet needs in Oncology and Autoimmune Diseases. The Company was founded in 2017 and launched earlier this year with a $10M Series A Preferred financing. RubrYc has developed the Interface Discovery Engine – the operating system the Company employs to realize critical efficiency gains in drug discovery. In its first quarter of operations the Company has grown its staff and made investments to capitalize on advantages conferred by the Interface Discovery Engine, and operate with a capital efficient ‘virtual biotechnology’ business model. Team RubrYc maintains intense focus on advancing its proprietary pipeline programs, while engaging in target-specific Platform Partnerships with industry incumbents.
ScalmiBio is an early stage company developing transformational technology focusing on oncology applications. We developed a novel technology that converts therapeutic antibodies into a prodrugs activated specifically within tumor. Therapeutics restricting their activity to tumor microenvironment will enable broader use of combination treatments, higher therapeutic doses, and limit side effects.
Scribe Biosciences is developing the next generation of high throughput single cell analysis tools for clinical and research applications. The company is based on Printed Droplet Microfluidics (PDM), a technology spun out of the Abate and Gartner labs at UCSF to enable the flexible and programmable handling of single cells with unsurpassed control. Scribe is currently being contracted by DARPA to build a single cell virology platform to enable the study of evolutionary processes in infectious diseases.
Siolta Therapeutics is leading scientific research aimed at the prevention and treatment of inflammatory diseases by harnessing the power of the human microbiome. Our current research and development is focused on the rational design of a mixed-species therapeutic microbial consortium to treat airway inflammation. We are working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics for inflammatory diseases.
Derived from the past. Designed for the future. Modern skincare as nature intended. Scientifically formulated using proven, ancestral ingredients to replace what has been lost in our modern world. Symbiome is the return to healthy skin.
Syncopation Life Sciences is an adoptive cell therapy company recently launched by founders from Stanford University in partnership with Samsara BioCapital. We are developing novel, CAR T-based technologies and programs to address important drivers of resistance to first-generation cell therapies. The company is based in the San Francisco Bay Area, where we are building a team of talented scientists and drug developers to bring a new generation of cell therapies to the clinic
SyntheX has a synthetic biology discovery platform for disrupting protein-protein. They design peptide-based compounds using their intracellular live/dead selection system to target the 'undruggable' space. Only 15% of the proteins within cells are considered 'druggable' by current enzymatic inhibitor drugs. Protein-protein interactions are considered 'undruggable' due to cumbersome assay readouts and the difficulty of achieving disruption with conventional small molecules. They are also select targets based on synthetic lethality - exploiting features unique and essential to tumor cells to obtain selectivity on a molecular basis.
Telo Therapeutics, Inc. is developing a novel, personalized medicine therapeutic to selectively inhibit cancer cell immortality. All cancer cells undergo a process called immortalization, and the majority of cancers achieve this by turning on an enzyme called telomerase. Telomerase is a validated clinical target, yet existing inhibitors are toxic to the body’s normal cells and have so far failed to make it to market. We are developing a novel therapeutic that will reverse immortality specifically in cancer cells and leave healthy cells intact.
Thelium Therapeutics is a preclinical stage company developing first-in-class, non-immunosuppressive small molecule therapies to restore epithelial barrier function in inflammatory diseases. We employ novel precision targeting approaches for barrier restoration that yields disease attenuation by taming immunological activation.
ThinkCyte has built the Ghost Cytometry technology, the world’s first high-throughput image-based cell sorting system by integrating advanced imaging, machine learning and microfluidics technologies. It enables researchers to identify cells based on their high content phenotypes (i.e. fluorescence and phase images) and isolate the target cells at high throughput, even without any labels. This innovative approach brings high-throughput, content-rich analysis and sorting on a single cell level to disciplines such as phenotypic drug screening and cell therapy.
Toray Industries Inc. is a chemical company originated from Japan, and has many business segments based on the chemistry (like Carbon fibers, Environmental engineering, wearable/medical devices and pharmaceuticals).
At MBC Biolabs, we perform the basic research of small-molecule drugs for the treatment of neurological diseases, especially itch, pain or neurodegenerative diseases.
Tradewind BioScience (TWB) is a company dedicated to creating novel, innovative therapeutics for the most aggressive, difficult to treat cancers. Our first therapeutic is a multifaceted attack antibody for cancer. What this means is that It works through multiple modes of action to detriment of malignant cells. We welcome your interest in TWB.
Tranquis Therapeutics is revolutionizing the treatment of neurodegenerative and aging-related diseases by targeting myeloid immune cell dysfunction. Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel portfolio of small molecule therapeutic candidates which cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. Our initial therapeutic programs target a master metabolic pathway that is downregulated in myeloid cells in patients with neurodegenerative diseases. Our candidate compounds are designed to reduce inflammation in dysfunctional myeloid cells and reprogram them to restore their normal immuno-metabolic function.
Trilo Therapeutics is a seed-stage company focused on the discovery of novel inhibitors of protein-protein interactions for therapeutic purposes. Our platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others.
TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering dual action drugs to generate immunogenic tumors. TRIO's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells in the tumor microenvironment. TRIO has an experienced team that has developed FDA-approved drugs.
Few know our skin better than the bugs who feed on it. Some of these embed in our skin for extended periods and have evolved incredible molecular toolkits for managing our response to invasion. At Trove Biolabs, we are mining this diverse cache to develop modern therapies for common skin conditions and diseases.
VastBiome is an engineering-first drug discovery company prospecting novel molecules from the human gut microbiome and developing them into standalone therapeutics starting with immunooncology. We are working to generate the largest database linking gut microbes to their chemical and immune axes of host response. Our vision is to move from identification and annotation of organisms, genes and metabolites to design whereby we can draw on these relationships to construct immunoregulatory drugs with specified function through synthetic gene expression composed from known biosynthetic units. Our approach leverages evolution at the human-microbe interface to bring patient immune regulation under precise control.
Vcreate is building a platform to accelerate the development of T-cell receptor (TCR) based therapies. TCR based therapies offer a promising alternative to CAR-T for solid tumors and other diseases, but identifying clinically relevant TCRs usually takes years and costs millions of dollars. We aim to dramatically reduce this development time -- from years to weeks -- through our novel TCR screening assays and machine learning models.
XCellAssay is pioneering innovative 'BioAssay' technologies that enable the low-cost measurement of hormones in ultra-low volumes of serum or urine that a patient can conveniently collect him/herself. Our technologies enable frequent measurement of the cumulative impact of all agents that affect a hormone's action and that are unique to each individual. That includes other natural hormones with similar actions, drugs and environmental contaminants that affect hormone action, and even serum proteins that bind the hormone.
To date, XCellAssay's studies have shown these integrative measurements to improve disease assessment in the two disease areas with others to follow. The improved relevance of the BioAssay measurements coupled with the low cost and increased frequency of monitoring will enable the tailoring of treatment to an individual's unique situation, permitting personalized health care delivery.
XCellAssay is currently expanding this capability to multiple hormone systems and disease states. XCellAssay's vision is to provide an integrated assessment of hormonal status for a variety of hormones and other biologic agents of high need within the clinical, drug discovery, and environmental communities.
Xomics is a pre-IND stage biopharma that strives to translate our rapidly expanding knowledge of transporter proteins into novel, first-in-class medicines to address unmet medical needs in treating cancer, metabolic disorders and genetic diseases. Xomics has operations in San Francisco Bay Area and Shanghai.
XPose Therapeutics is an early stage drug discovery company leveraging a cutting-edge approach using experimental information on 3D protein-ligand interactions as a starting point to discover and develop target-specific small molecule cancer therapeutics for traditionally “undruggable” targets. Our focus is on DNA damage response (DDR) proteins and their demonstrated roles in cancer. The compounds we discover and develop can be deployed in a multi-pronged approach across multiple modalities: monotherapy involving conventional enzyme inhibition; synthetic lethality (SL); targeted-protein degradation (PROTAC); and combinatorial therapy, thereby providing a significantly large therapeutic landscape to help a wide variety of patients. XPose joins MBC BioLabs supported by non-dilutive funding from the NCI through SBIR Phase I funding.
4DMT is a global leader in gene therapy product research & development. 4DMT and our partners are using scientific innovation to unlock the full potential of gene therapy for patients with genetic diseases. Our robust discovery platform, termed Directed Vector Evolution, empowers us to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. These customized products allow us to deliver normal genes to tissues with defective genes (as occurs in genetic diseases).
AesculaTech engages in the development of smart materials for medical devices. Our first product is a treatment for the millions of Americans in the US that suffer from dry eye syndrome. The device is one‑size-fits-all and easy to administer, resulting in improved patient comfort, better outcomes and fewer repeat procedures.
Alector,one of QB3@953’s first companies, is moving on to more spacious locations to continue its development of novel immuno-modulating therapeutics for neurodegenerative diseases. After successfully raising over $60M in 2015 alone and developing multiple clinical candidates, Alector will continue its work in two locations south of our fair city.
Alaunus Biosciences is a preclinical-stage immune-oncology company using a proprietary technology platform to address unmet clinical needs in cancer diagnosis and treatment We take advantage of the unique protease activity signature present in the tumor microenvironment, and leverage it to develop protease-activated cancer therapeutics and protease-based prognostic biomarkers. We are initially focusing our technology on developing a laboratory-based assay for risk stratification and early detection of pancreatic cancer, by identifying pre-malignant cysts in the pancreas before they develop into full tumors.
Our mission is to create a more humane and sustainable food system by removing animals from the process of making food. Alpine is developing alternative ways to produce animal protein by nutritionally enhancing plants.
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
AOBiome LLC is developing first-in-class topical biologics for the treatment of inflammatory skin conditions. We have developed extensive scientific and manufacturing expertise on the use of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring bacteria that metabolize the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties.
The therapeutic potential of nitrite and nitric oxide are widely recognized, although as yet, largely unrealized as delivery, let alone targeted delivery is extremely difficult. The company's proprietary AOB offers the potential of a first-in-class natural delivery system for nitrite and nitric oxide.
Autodesk Life Sciences delivers a single, integrated cloud-enabled software solution that enhances the disjointed and legacy systems used in today’s discovery process.
With software that's easy for scientists to use, simple for coders to extend, and built with collaboration at its core, Autodesk Life Sciences is building a cloud platform for the next generation of biological design.
Bell Biosystems, Inc. is a synthetic biology company based in San Francisco, CA. Our vision is to pioneer the use of synthetic organelles to accelerate product development through discovery, innovation and collaboration.
Blueprint Genetics is applying a powerful molecular biology approach called next-generation sequencing to analyze patients’ DNA. Changes in DNA sequence can cause errors in proteins and result in severe medical conditions. Genetic disorders include hereditary diseases that are caused by mutations originating in germ cells and presenting in all cells of an individual, and cancers that occur through sequential accumulation of genetic alterations in somatic cells that typically arise over long period of time. Determining the underlying DNA changes creates opportunities to diagnose genetic disorders, estimate prognosis and select preventive treatments.
Next-generation sequencing is enabling comprehensive analysis of hundreds of clinically relevant target genes in a time frame that facilitates clinical reactions. Sequencing detects different types of mutations exchanging single nucleotides (point mutations), adding or removing nucleotides (insertions and deletions) or resulting in larger alterations in chromosomal structure.
Blueprint Genetics is applying a targeted sequencing approach called oligonucleotide-selective sequencing “OS-Seq™” (Myllykangas et al 2011) that was developed in Stanford University to analyze disease-specific gene panels. With targeted sequencing it is possible to identify all mutations that have been previously linked to specific genetic disorders as well as novel variants in the disease-associated genes.
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
CAPP Medical, founded in 2013 by Stanford oncologists and industry veterans, has novel technology designed to isolate and quantify small amounts of ctDNA through a simple blood draw, which has the potential to be used for cancer therapy selection and monitoring tumor response and resistance in therapy.
Roche Acquired CAPP Medical to Strengthen Cancer Diagnosis in April 2015.
Cell Design Labs, a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases, has been a part of QB3 since March 2016. Based on innovative research from Dr. Wendell Lim's lab at UCSF, Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the potential to treat our most challenging diseases with unprecedented power, precision, safety and durability. While at QB3@953, Cell Design Labs grew from 3 to 20, raised $34M, and established a large partnership with Kite - not bad in a year. Now they have moved on to the East Bay.
CellFE (Cell Fluidics Engineering) brings innovative technology to engineer the next generation of cell therapies to fight cancer and other challenging diseases. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering – how to efficiently deliver gene-editing molecules into cells while preserving cell viability.
CHO Plus is engaged in engineering new generations of mammalian cell lines for the production of Human biopharmaceuticals. Our goal is to provide highly productive GMP-compliant cell lines to satisfy our customers' clinical and commercial manufacturing needs.
CLEO Life Sciences is a unique hybrid model of Chemistry, Manufacturing, and Controls (CMC) consulting combined with a small-scale R&D prototyping lab for pharmaceutical formulation development. We support clients with nimble prototyping of products and processes, using reduced quantities of API and starting formulation development earlier in the drug development cycle. CLEO is able to facilitate rapid efficient tech transfers to GMP contract manufacturing sites, troubleshooting, and scale-up. We enable product & process development on highly accelerated timelines and improve management of CMC technical and execution risks.
Darmiyan's fully automated proprietary software platform inputs human brain MRI and produces maps that detect Alzheimer’s disease up to fifteen years before symptoms. It is impossible to find a cure for Alzheimer’s without early detection, and that's why drug candidates fail one after another. Their mission is to create a fast, non-invasive, inexpensive, precise and globally accessible tool for brain health screening and monitoring. This will help millions of people worldwide who suffer from brain diseases to be diagnosed early and get treated.
Delpor is a clinical stage life sciences company that utilizes innovative drug delivery technologies to develop new therapeutic products which are based on approved drugs. Our goal is to improve a patient’s quality of life by developing once yearly therapies for chronic conditions.
Dren bio is a biotechnology company developing engineered protein and cellular therapies for depletion of pathological cells and other disease causing agents. Dren is developing products to treat certain leukemias, lymphomas and autoimmune disorders, with the potential to expand into other disease areas.
Enable Biosciences is developing 1000x more sensitive antibody tests for the early detection and treatment of diseases like HIV and type 1 diabetes. Their technology was invented at UC Berkeley and Stanford by Jason Tsai and Peter Robinson in the lab of Carolyn Bertozzi in 2015. Joined by Dr. David Seftel, MD/MBA, Enable's cofounders have participated in UCSF's Lean Launchpad and Startup 101 programs in addition to Stanford's StartX accelerator program. They are the recipients of grants from the NIH, NSF, and Stanford to develop their technology and won the 2016 Harvard Business School New Ventures Competition for Northern California.
Excel BioPharm is developing an innovative technology platform that allows reliable and efficient generation of antibodies targeting multi transmembrane proteins such as GPCRs, transporters, and ion channels. The technology will be made available to strategic collaborators and partners developing antibody therapeutics. In the meantime, the Company offers custom antibody services, using both established and novel proprietary approaches, to customers interested in developing high quality antibodies in research, in vitro diagnostics, and therapeutic applications.
ExcepGen is developing better therapeutics by using authentic human proteins in drug discovery. With its novel platform, the company is discovering antibodies against previously impossible targets and pursuing new therapeutic proteins.
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. We have built a transformative model of aging that re-creates many of the complex hallmark features of aging, but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics. We work toward our vision of a future in which we extend healthy lifespan and slow aging itself.
Fustibal is a biotechnology startup focused on fostering affordable healthcare through simpler science. To evolve the medical industry, our team dissects life science big data through scientific investigation, reverse engineering, data mining, and computational modeling. In synergy with our drug targeting platform, we design genomic- and proteomic-driven pharmaceuticals. Our mission is to develop economical and accessible molecular diagnostics and therapeutics.
FutureGen BioMed is a biotechnology company headquartered in San Francisco, California. We offer fully integrated and top quality services including antigen & antibody discovery, production and characterization etc. to both academia and the biopharmaceutical industries. FutureGen guarantees that the services will be conducted efficiently, cost-effectively, well documented, and our clients will be updated with actual experimental progress throughout the course.
GeneTether is an early stage biotechnology company developing improved gene editing technologies using Crispr/Cas, TALEN, and Zinc-Finger nucleases for human therapeutic applications. We are developing an approach that gives the DNA repair-templates the same “address” as the DNA strand breaks, ensuring their presence when needed for gene editing. This could improve gene editing efficiencies by over 100x while reducing unintended unwanted DNA damage and mutation.
Geoffrey Sargent, PhD is founder and CEO. Geoff has over 28 years in biotech and academia working in the fields of DNA damage, DNA repair, and DNA recombination in mammalian cells. He has led teams developing gene editing technologies in biotech and used a precursor technology to Crispr/Cas9, TALEN, and Zinc-Fingers to study the repair of DNA double strand breaks in mammalian cells.
We strive to create a world where anyone, anywhere in need of blood or an organ gets the right blood or organ that is safe, accessible and affordable. We will be guided by our Core Values of Respect, Integrity, Teamwork and Achievement. In doing so, we will strive to achieve the highest quality products and solutions, bring forth and pursue innovations that advance patient safety and
honor our customers with the highest level of service.
indee was founded on the idea that everyone should be able to access safe, effective and affordable healthcare designed to deliver optimal patient outcomes. We believe our patent pending technology will enable gene therapy for the masses.
Sepsis (a complication of some infections) is associated with half of all in-hospital deaths, and is the single most expensive diagnosis nationally ($24 billion). There is no rapid gold standard diagnostic, so physicians largely guess at presence and severity of infection. Blood cultures, which may take 24-48 hours to return, only turn positive in ~30% of all patients with infections, and so are not effective for ruling out infections.
Inflammatix (pronounced in-flah-MATT-iks) has a breakthrough solution: we ‘read’ the immune system to determine the presence, type (bacterial/viral) and severity of infection. The technique works by measuring the expression levels of several host immune genes, and then applying proprietary Inflammatix algorithms to produce clinically actionable results. The Inflammatix gene sets have been extensively validated (24 validation cohorts, >1000 patients) and published in top-tier medical journals.
Leadhexa Biotechnologies, Inc. is a Delaware corporation, whose founders have discovered a unique version of the enzyme Manganese SuperOxide Dismutase (MnSOD) which stunningly has the ability to enter cells and mitochondria. The molecule has demonstrated efficacy in numerous preclinical models including actinic keratosis, tumor suppression, radiation protection, protection of kidney damage due to cyclosporine or contrast dye, liver cirrhosis and liver ischemia-reperfusion injury.
Mammoth Biosciences is an early stage startup founded by Stanford PhDs that is developing the next generation diagnostics platform using recent advances in CRISPR technology. We are enabling everyone to have access to rapid, low cost, and easy to use tests for identifying DNA and RNA sequences. Our initial market focus is infectious disease testing, but we plan on rapidly expanding into many market verticals and across industries.
Mattershift designs and manufactures nanotube membranes for biofuels, carbon zero fuels, cell-free biological processes, and precise molecular separations and synthesis. The ultimate goal is to realize the promise of molecular factories that print matter from the air.
MedGenome Inc. is a genomics-based diagnostics and research company delivering the best of health care by decoding genetic information contained in an individual’s genome. We are the first mover and market leader in genomics-based diagnostics and research from India with global offices in California.
Our mission is to improve global health by developing deep insights into diseases at the genetic and molecular level. Our research solutions apply cutting-edge genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large South Asian population to understand the genetic basis of cancer, metabolic disorders, eye disorders and other rare diseases. We also address important research questions in hereditary diseases, cardiovascular complications and neurological disorders.
Miroculus has developed a novel digital microfluidics technology to automate and miniaturize genomic protocols such as NGS library prep, synthetic biology, cell editing, and combinatorial chemistry, in a compact, user-friendly system.
Naked Biome is using bacteria to fight bacteria, they are seeking to treat skin diseases, particularly acne, by creating a healthy skin microbiome. This terrific team is led by Dr. Emma Taylor, and will be joined here by David Hanzel, Iden Haddadzadeh, and Shreyasee Chakraborty.
Neopeutics is an early stage drug discovery contract research partner. We offer our clients and partners a robust and cost effective set of tools that can be utilised in a variety of contexts in the drug discovery process.
Safe and ultra-fast charging batteries are a very important need in the rapidly growing Electric Vehicles (“EV”) market. Next-ion has developed a unique universal membrane that enables a new, ultra-fast charging battery (i.e. charging rates up to 10C or more). With this turn-key, drop-in technology, Next-Ion hopes to partner with existing and emerging players and companies in the energy storage space to enable the next generation storage technology solutions.
Nirmidas Biotech, Inc. develops, manufactures, and markets breakthrough biological testing, assay and imaging technologies, based on a novel red to near infrared fluorescence (700-1700 nm) detection and imaging platform. We aim to develop personal and portable diagnostics systems for early disease diagnosis and prognosis monitoring, as well as for population-based screening. We also aim to develop an in vivo imaging systems for research, diagnosis, and therapeutics. Our products lie at the intersection of life science research, in vitro diagnosis, in vivo imaging, and digital healthcare.
Nitrome Biosciences is developing drugs against a new class of enzymes, initially targeting Parkinson’s disease. When successful, we will have founded and characterized the class of enzymes, which we call Nitrases, and will have paved a novel inroad into the proprietary development of disease-modifying drugs for multiple additional aging-dependent diseases. We are starting with Parkinson’s disease but this may be extended to include other neurodegenerative diseases, heart disease and cancer.
Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.
OpenCovidScreen is a non-profit organization working towards a rapid, low-cost COVID-19 test. Clinical testing currently costs ~$100/sample with results delivered after several days. We seek a test for “less than the price of a latte” (<$5) with next-day or faster results. The test development is an open-source effort, so that anyone can adopt our solutions. In the first phase of our efforts, we are partnering with the XPRIZE Foundation to hold a competition to catalyze the invention of new technologies. Competition winners will enter pilot studies for further validation. A successful test will then be chosen for scale-up and dissemination to schools, businesses, nursing homes, prisons, and other hotspots around the globe.
Pionyr (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the third generation of immuno-oncology therapeutics after checkpoint inhibitors and CAR-T. The company's approach, Myeloid Tuning™, is designed to enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor micro-environment with high specificity.
pH Pharma’s vision is to discover and develop distinctive and innovative healthcare technologies and therapies. Our therapeutic candidates in clinical development target glaucoma and metabolic syndromes. We are also focused on a pre-clinical program to discover novel oncology therapeutics. pH Pharma was founded in 2015 and is headquartered in Seoul, South Korea with a main Silicon Valley office in Menlo Park, California.
Prellis Biologics is developing technology to build transplantable human organs and tissues. Our aim is to address the organ shortage and provide human tissues to streamline the development of therapeutics. The first transplantable human tissues Prellis Biologics is working to develop are the insulin secreting units of the pancreas, Islets of Langerhans. A renewable, safe source of Islets of Langerhans will provide an option to millions of people living with Type 1 Diabetes Mellitus (T1DM). An islet transplant may allow T1DM patients to become insulin independent thereby avoiding daily injections and finger pricks for monitoring and regulating dangerous blood sugar swings. In addition, our company has developed a printing process to create human Lymph Node Organoids (LNO), capable of immune responses and generation of human antibodies, bypassing the need for antibody development in animals. In our proof-of-concept studies, our scientists created 14 novel class-switched human IgG antibodies that are reactive to the Zika Virus in less than 6 weeks. By engineering human tissues in the laboratory for rapid therapeutics development, our technology will streamline bench-to-bedside research and efficiently address emerging disease outbreaks. Prellis Biologics was co-founded in 2016 by Dr. Melanie Matheu and Dr. Noelle Mullin, two PhDs with a passion for bringing engineering and biology together to solve unmet medical needs.
Proxeom is focused on improving cancer survival with technologies for highly-sensitive detection of mutations in circulating cell free DNA enabling early detection, monitoring progression or regression of cancer, detecting metastasis and predicting relapse. By sampling blood and body fluids such as urine, semen, uterine exudates, etc. for mutational signatures of cancer; the non-invasive, liquid biopsy based approach can detect the presence of a tumor in the body as well as provide guidance on therapy.
Quartz is bringing together chemical and biological expertise to develop effective therapies for patients suffering from RAS-driven cancers. They are targeting key steps in the MAPK pathway with a novel degradation technology and have plans to be in the clinic by 2019.
Revitope is developing a novel approach to cancer immunotherapy. Cancer patients typically have strong cytotoxic immunity against viral pathogens while lacking immunity against their tumors. Revitope’s technology redirects an exisiting viral immune response to treat cancer. Revitope’s antibody peptide epitope complex (APEC) technology selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it. Revitope is backed by a strong team of scientific founders, management team and investors. The company’s goal is to harness its platform to develop multiple therapeutics for the treatment of solid tumors and hematologic malignancies. Revitope is headquartered in San Francisco. Revitope’s founders are based in Boston, at Harvard/Massachusetts General Hospital.
RUMI Scientific seeks to revolutionize the landscape of drug discovery through its proprietary human stem cell technology that uses single-cell, time-lapse imaging and customized analytic tools to inexpensively and more effectively identify treatments for human genetic diseases. With RUMI’s micropattern technology, human embryonic stem cells self-organize to generate a signature defined by geometry and size, driven by processes that occur in vivo as the cells differentiate to give rise to different human cell types. Many disease-causing mutations will change the signature. The use of isogenic cell lines recapitulating mutations that are causal to human diseases can be applied to high-throughput screens to identify compounds that revert the disease signature back to normal. This technology allows a high-resolution evaluation of cellular behaviors comparatively between normal and disease state, providing an opportunity to perform “clinical trials on human micropatterns”.
Safe-H2O Inc. is a water bio detection company providing rapid pathogen test systems and data services; assisting water providers and water treatment service providers in reducing fatalities and illness related to waterborne pathogens and assuring sustainability of water systems.
Few people know that in only one out of three cancer patients benefit from first line anti-cancer therapy. This is because every tumor is unique and thus knowing which therapy would work best in an individual patient remains a major challenge for oncologists. SageMedic is working feverishly on a test of the patient’s biopsy to guide oncologists in picking the most effective treatment to double their chance of tumor response, quality of life, and life expectancy.
Every body is unique.
No two people are exactly alike.
Sano uncovers the unique biometric information that’s vital to understanding your health. Our mobile app provides easy access to your current glucose levels and historical trends to turn insight into action.
Scaled Biolabs accelerates discovery and translation of cell therapies, to improve quality of life through regenerative medicine. Their core technology uses a miniaturized cell culture lab which runs nearly 10,000 experiments in parallel, and an advanced bioinformatics platform that turns single-cell resolution data into deep biological insight. They use this optimization engine to relieve the R&D bottlenecks of companies bringing on complex, advanced medicines such as cell therapies.
Single Helix Genomics is a collection of engineers, scientists and executives determined to provide cGMP compliant products of custom and pre-designed RNA for drug discovery and distributed manufacturing of mRNA therapeutics and vaccines accomplished on a proprietary single-use microfluidic biochip. We have developed an automated and portable therapeutics-on-demand (TOD) device that enables consistent, small-scale current good-manufacturing-practice (cGMP) manufacturing of therapeutics-grade mRNA on a timescale of hours.
SiteOne is a biotech founded by Stanford University researchers to develop safer, more effective, non-narcotic pain medicines for acute and chronic pain management. SiteOne is also advancing novel molecular diagnostics for locating pain generators – information that would more accurately guide the treatment of chronic pain. Our therapeutic and imaging agents target sodium channels in pain-sensing nerves. The therapeutic program applies our proprietary chemistry to target the 1.7 sodium channel subtype and the imaging program is developing novel PET ligands.
Sound Agriculture, formerly known as Asilomar Bio, is developing technologies to help growers sustainably increase productivity by enhancing crop nutrient and water use. The Company is working to launch its first products in collaboration with partners.
Symic Bio is a biopharmaceutical company developing a new category of therapeutics focused on matrix biology. The (extracellular) matrix is the non-cellular component of the body’s tissues and can be envisioned as a sponge-like environment surrounding the cells of a tissue. In this environment, cells proliferate, migrate and differentiate. Research in recent decades has demonstrated the biological importance of the interactive and dynamic relationship between cells and their matrix environment. The Symic Bio platform of matrix-targeting biotherapeutics builds upon this research. These therapeutics, inspired by naturally occurring macromolecules of the matrix called proteoglycans, bind to targets in the matrix damaged in response to injury or because of disease. They are designed to inhibit pathological inflammatory responses and to affect matrix degradation and structure.
Synimmune Inc. is a biotechnology company aiming to commercialize our company’s own immune-oncology products as well as providing R&D services to partner companies that develop immunotherapies to treat patients with cancer. The company’s Monoclonal TCR Technology facilitate the generation of novel tumor specific TCRs for the development of adoptive T cell therapy. The company’s Antigen Discovery Platform enable functional identification of neoantigens for the development of personalized cancer vaccines.
Teon Therapeutics is a global biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy. Headquartered in the San Francisco Bay Area and backed by Venture Capitals, Teon is committed to advance innovative therapeutic agents to address unmet global medical needs and improve the lives of patients.
To improve long-term outcomes for more patients with cancer, Teon Therapeutics believes more Immuno-Oncology based combinations may be required. With this core philosophy in mind, their first-in-class small molecule checkpoint inhibitors (A2B & UDT-1) are the backbone of our IO portfolio and offer differentiated combination therapies with our other potentially best in-class checkpoint inhibitors.
Teon’s executive team has extensive pharmaceutical industry experience and a proven track record of successful drug discovery, development and launching in multiple therapeutic areas.
TB-SEQ, Inc. is a life sciences company based in San Francisco, CA. TB-SEQ has developed a platform technology based on NGS sequencing for discovering and monitoring expression of proteins and regulatory peptides. TB-SEQ's technology greatly facilitates functional-genomics and protein-biomarker identification analyses in biomedical, pharmaceutical, and agricultural applications.
Tiatros offers safe and affordable evidence-based group psychotherapies inside HIPAA compliant private social networks, where patients learn CBT+ skills and practice them with others who have similar health challenges and goals. Tiatros captures the unstructured data contained in psychiatric evaluations, patient narratives and interactions, preserving their clinical richness. We're working with leading cognitive computing and AI vendors to revolutionize the delivery of psychotherapies.
Trace Genomics is building an artificial intelligence and genomics platform to tackle agricultural diseases. Our genomics-based infectious disease panel digitalizes sample states, delivering actionable information to farmers to enable precision agriculture. Our vision is to build a global database of emerging and significant pathogens and enable data-driven product design for agriculture using machine learning.
ViewPoint Therapeutics is dedicated to the discovery, development, and commercialization of treatments for protein misfiling diseases, including cataracts. Their initial focus is crystallin biology. To address the global need for new methods to treat cataracts and presbyopia, they are pioneering the development of crystallin stabilizers to stabilize the functional form of the crucial human lens protein alpha-crystallin against accumulated damage. By developing VP1-001 as a small molecule medicine suitable for topical application, Viewpoint hopes to revitalize the treatment paradigm for vision loss associated with presbyopia and cataracts.
ViewPoint was founded in July of 2014 based on technology developed in the lab of Jason Gestwicki at the University of Michigan – now professor at UCSF, in collaboration with the lab of Usha Andley at Washington University in St. Louis, and is led by Leah Makley, CEO.
In every one of us there are there are millions more bacterial genes than human ones. This microbiome, comprised of all of the microorganisms inhabiting us, represents a significant opportunity for improving human health. Whole Biome will provide health product, pharmaceutical and research organizations with the CompleteBiome Test(™) that contains clinically-relevant information on this complex ecosystem. This will enable a revolution in personalized medicine where each individual’s treatment will be driven by a comprehensive understanding and a targeted equilibration of their microbiome.
At Zymergen, we engineer biology predictably, reliably and to a level of performance previously unattainable through traditional R&D. We work with Fortune 500 companies that span industries, including chemical and materials, agriculture, and healthcare.
Zymergen works with our customers to improve the economics of existing industrial fermentation products. Our platform enables us to build improvements into their existing production strains within their existing manufacturing processes. We augment our customers’ capabilities and help them get more out of their existing capital assets. Zymergen has a track record of improving capital utilization for customers’ existing products, accelerating time-to-market for new products, and delivering significant cost reductions for both.